H

Herantis Pharma Oyj
OMXH:HRTIS

Watchlist Manager
Herantis Pharma Oyj
OMXH:HRTIS
Watchlist
Price: 1.32 EUR 7.32% Market Closed
Market Cap: 26.6m EUR
Have any thoughts about
Herantis Pharma Oyj?
Write Note

Profitability Summary

Herantis Pharma Oyj's profitability score is 47/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

47/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

47/100
Profitability
Score
47/100
Profitability
Score

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Herantis Pharma Oyj

Revenue
0 EUR
Operating Expenses
-193.6k EUR
Operating Income
-193.6k EUR
Other Expenses
-418.5k EUR
Net Income
-612.2k EUR

Margins Comparison
Herantis Pharma Oyj Competitors

Country Company Market Cap Operating
Margin
Net
Margin
FI
Herantis Pharma Oyj
OMXH:HRTIS
26.6m EUR N/A N/A
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
-79%
US
Eli Lilly and Co
NYSE:LLY
710.5B USD
35%
20%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
-4%
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK
44%
35%
US
Johnson & Johnson
NYSE:JNJ
373.5B USD
28%
17%
US
Merck & Co Inc
NYSE:MRK
251.1B USD
34%
19%
CH
Roche Holding AG
SIX:ROG
202.7B CHF
32%
20%
CH
Novartis AG
SIX:NOVN
183.3B CHF
31%
35%
UK
AstraZeneca PLC
LSE:AZN
162.4B GBP
21%
13%
IE
Endo International PLC
LSE:0Y5F
146B USD
11%
-126%
Country FI
Market Cap 26.6m EUR
Operating Margin N/A
Net Margin N/A
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Net Margin
-79%
Country US
Market Cap 710.5B USD
Operating Margin
35%
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Net Margin
-4%
Country DK
Market Cap 3.3T DKK
Operating Margin
44%
Net Margin
35%
Country US
Market Cap 373.5B USD
Operating Margin
28%
Net Margin
17%
Country US
Market Cap 251.1B USD
Operating Margin
34%
Net Margin
19%
Country CH
Market Cap 202.7B CHF
Operating Margin
32%
Net Margin
20%
Country CH
Market Cap 183.3B CHF
Operating Margin
31%
Net Margin
35%
Country UK
Market Cap 162.4B GBP
Operating Margin
21%
Net Margin
13%
Country IE
Market Cap 146B USD
Operating Margin
11%
Net Margin
-126%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Herantis Pharma Oyj Competitors

Country Company Market Cap ROE ROA ROCE ROIC
FI
Herantis Pharma Oyj
OMXH:HRTIS
26.6m EUR
-662%
-14%
-9%
35%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-441%
-47%
-108%
-64%
US
Eli Lilly and Co
NYSE:LLY
710.5B USD
66%
13%
33%
19%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK
89%
27%
75%
35%
US
Johnson & Johnson
NYSE:JNJ
373.5B USD
20%
8%
18%
13%
US
Merck & Co Inc
NYSE:MRK
251.1B USD
28%
11%
25%
20%
CH
Roche Holding AG
SIX:ROG
202.7B CHF
40%
13%
29%
22%
CH
Novartis AG
SIX:NOVN
183.3B CHF
45%
17%
24%
16%
UK
AstraZeneca PLC
LSE:AZN
162.4B GBP
17%
6%
14%
12%
IE
Endo International PLC
LSE:0Y5F
146B USD
70%
-51%
5%
6%
Country FI
Market Cap 26.6m EUR
ROE
-662%
ROA
-14%
ROCE
-9%
ROIC
35%
Country JP
Market Cap 776 550.9T JPY
ROE
-441%
ROA
-47%
ROCE
-108%
ROIC
-64%
Country US
Market Cap 710.5B USD
ROE
66%
ROA
13%
ROCE
33%
ROIC
19%
Country UK
Market Cap 440.4B GBP
ROE
-4%
ROA
-2%
ROCE
2%
ROIC
2%
Country DK
Market Cap 3.3T DKK
ROE
89%
ROA
27%
ROCE
75%
ROIC
35%
Country US
Market Cap 373.5B USD
ROE
20%
ROA
8%
ROCE
18%
ROIC
13%
Country US
Market Cap 251.1B USD
ROE
28%
ROA
11%
ROCE
25%
ROIC
20%
Country CH
Market Cap 202.7B CHF
ROE
40%
ROA
13%
ROCE
29%
ROIC
22%
Country CH
Market Cap 183.3B CHF
ROE
45%
ROA
17%
ROCE
24%
ROIC
16%
Country UK
Market Cap 162.4B GBP
ROE
17%
ROA
6%
ROCE
14%
ROIC
12%
Country IE
Market Cap 146B USD
ROE
70%
ROA
-51%
ROCE
5%
ROIC
6%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top